Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker ...
and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will ...
As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...
MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...
As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Alterity Therapeutics (ATHE) stock jumps as its lead asset, ATH434, shows promise in slowing clinical progression in multiple ...
Stockhead on MSN8d
Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorderfor fast-track approval of its treatment for multiple system atrophy (MSA). Alterity shares soared up to 112% this morning ...
An incredible life of extraordinary kindness, service, and humble achievement came to a close Feb. 1, 2025 with the passing ...
Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback